Why the study?
Despite arrhythmias contributing to morbidity, in-hospital mortality, and sudden death in PAH and CTEPH, epidemiologic, pathophysiologic, and outcome data to guide management remain limited.
Arrhythmias are increasingly recognized as serious, end-stage complications of PAH and CTEPH, necessitating a better understanding of their pathophysiology and management.
Arrhythmias warrant heightened clinical vigilance in PAH/CTEPH; this synthesis extends mechanistic and epidemiologic insights while leaving open targeted trials.
Arrhythmias are increasingly recognized as serious, end-stage complications of pre-capillary pulmonary hypertension, including pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Although arrhythmias contribute to symptoms, morbidity, in-hospital mortality, and possibly sudden death in PAH/CTEPH, there remains a paucity of epidemiologic, pathophysiologic, and outcome data to guide management of these patients. This review summarizes the most current evidence on the topic: from the molecular mechanisms driving arrhythmia in the hypertrophied or failing right heart, to the clinical aspects of epidemiology, diagnosis, and management.
No takes yet. Share an insight, caveat, or question.
Cirulis et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: